# A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

> **NCT07365826** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Vaxcyte, Inc.** · enrollment: 1390 (actual)

## Conditions studied

- Pneumococcal Vaccines

## Interventions

- **BIOLOGICAL:** 31-valent pneumococcal conjugate vaccine
- **BIOLOGICAL:** Seasonal Influenza Vaccine (SIV) (Flublok)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07365826
- **Lead sponsor:** Vaxcyte, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 1390 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365826, "A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07365826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*